Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Psychiatry. 2001 Apr;158(4):635-7.

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.

Author information

1
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland at Baltimore, P.O. Box 21247, Baltimore, MD 21228, USA. eweiner@mprc.umaryland.edu

Abstract

OBJECTIVE:

The study examined the efficacy, tolerability, and safety of supportive group psychotherapy and adjunctive sustained-release bupropion for nicotine addiction in patients with schizophrenia.

METHOD:

Eight patients participated in a 14-week open-label trial. End expired breath carbon monoxide level, symptom levels, neuropsychological performance, and suppression of the P50 event-related potential were measured before and after the 14-week trial.

RESULTS:

Patients showed a decrease in carbon monoxide levels that was not associated with any worsening in symptom, neuropsychological, or P50 suppression measures.

CONCLUSIONS:

Use of sustained-release bupropion in combination with supportive group therapy may help patients with schizophrenia decrease their cigarette consumption.

PMID:
11282701
DOI:
10.1176/appi.ajp.158.4.635
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center